Pattern of Use of Bevacizumab or Cetuximab + FOLFIRI Regimen as First-line Treatment in Metastatic Colorectal Cancer

Last updated: April 21, 2021
Sponsor: Joong Bae Ahn
Overall Status: Active - Recruiting

Phase

N/A

Condition

Colorectal Cancer

Metastatic Cancer

Treatment

N/A

Clinical Study ID

NCT03286738
CTP_401
  • Ages > 19
  • All Genders

Study Summary

  • Registry

  • Multicenter, prospective observational study

  • Observe adverse events and efficacy in recruited patients for 3 years under real world settings.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  1. Adult patients at least 19 years of age with metastatic colorectal cancer who areplanned to receive Bevacizumab or Cetuximab in combination with FOLFIRI regimen asfirst-line treatment
  2. Patients who will receive irinotecan, a component of FOLFIRI regimen, using CamtopInjection®

Exclusion

Exclusion Criteria:

  1. Patients with conditions in which any study drug is contraindicated per the respectiveapproved label.

Study Design

Total Participants: 1800
Study Start date:
November 01, 2015
Estimated Completion Date:
December 31, 2021

Connect with a study center

  • Yonsei University Health System, Severance Hospital

    Seoul, 03722
    Korea, Republic of

    Active - Recruiting

Map preview placeholder

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.